Heterogeneous cancers like AML (acute myeloid leukemia) are increasingly being treated with targeted therapies. To better inform treatment, the mutational content of patient samples must be determined. However, current tumor sequencing paradigms are inadequate to fully characterize many instances of the disease. A major challenge has been the unambiguous identification of potentially rare and genetically heterogeneous neoplastic cell populations, capable of critically impacting tumor evolution and the acquisition of therapeutic resistance. Single-cell DNA analysis has the potential to address these key issues and transform our ability to accurately characterize clonal heterogeneity.
In this webcast, collaborators from University of Pennsylvania and University of California San Francisco will discuss their findings in a study of the FLT3 inhibitor gilteritinib in relapsed/refractory AML and how single-cell DNA analysis may enable dynamic therapy selection.